Pfizer submits initial trial data for COVID vaccine for children five to 11

The COVID-19 pandemic could soon be one step closer to being over.

Pfizer has indicated they have submitted initial trial data to Health Canada for the use of their COVID-19 vaccination for children ages five to 11.

The initial trials saw Pfizer test a much lower dose — a third of an amount given to adults — in a study involving close to 2,300 elementary or kindergarten-aged children. After receiving the second dose, the study shows the children had antibody levels just as high as teenagers or young adults who received regular strength shots.

There are no vaccines currently approved for use for children under the age of 12 in Canada.

Moderna is also studying the effects of their COVID-19 vaccine in children in the same age group.

Both vaccine companies are also studying on children as young as six months of age. Those results are expected to come out later this year.

More from Play92